GSK Reports P-III (AReSVi-006) Study Results of RSVPreF3 OA for the Treatment of Respiratory Syncytial Virus
Shots:
- The P-III (AReSVi-006) study evaluating a single dose of RSVPreF3 OA vaccine in ~25,000 adults aged ≥60yrs. with RSV across 17 countries
- The trial met its 1EPs i.e., overall vaccine efficacy of 82.6% against RSV- LRTD, consistent high vaccine efficacy across a range of pre-specified 2EPs, high vaccine efficacy against LRTD in sev. disease (94.1%), adults aged 70-79yrs. (93.8%) and in patients with pre-existing comorbidities (94.6%)
- Vaccine efficacy against LRTD was consistent across RSV-A & B subtypes (84.6% & 80.9) & robust neutralizing Ab response against both subtypes, was well tolerated with a favorable safety profile. The regulatory submissions are expected in H2’22, based on the P-III results
Ref: GSK | Image: GSK
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
